Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix When Administered According to the Approved Prescribing Information in Korea

NCT03671369 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03671369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03671369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix When Administered According to the Approved Prescribing Information in Korea
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
October 2, 2018
Completion date
December 1, 2020
Enrollment
670 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, rectal